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Objective To compare time to diagnosis of the typically slow-
growing Type I (low-grade serous, low-grade endometrioid,
mucinous, clear cell) and the more aggressive Type II (high-grade
serous, high-grade endometrioid, undifferentiated,
carcinosarcoma) invasive epithelial ovarian cancer (iEOC).
Design Multicentre observational study.
Setting Ten UK gynaecological oncology centres.
Population Women diagnosed with primary EOC between 2006
and 2008.
Methods Symptom data were collected before diagnosis using
patient questionnaire and primary-care records. We estimated
patient interval (first symptom to presentation) using questionnaire
data and diagnostic interval (presentation to diagnosis) using
primary-care records. We considered the impact of first symptom,
referral and stage on intervals for Type I and Type II iEOC.
Main outcome measures Patient and diagnostic intervals.
Results In all, 78% of 60 Type I and 21% of 134 Type II iEOC were
early-stage. Intervals were comparable and independent of stage
[e.g. median patient interval for Type I: early-stage 0.3 months
(interquartile range 0.3–3.0) versus late-stage 0.3 months
(interquartile range 0.3–4.5), P = 0.8]. Twenty-seven percent of
women with Type I and Type II had diagnostic intervals of at least
9 months. First symptom (questionnaire) was also similar, except
for the infrequent abnormal bleeding (Type I 15% versus Type II
4%, P = 0.01). More women with Type I disease (57% versus 41%,
P = 0.04) had been referred for suspected gynaecological cancer.
Median time from referral to diagnosis was 1.4 months for women
with iEOC referred via a 2-week cancer referral to any specialty
compared with 2.6 months (interquartile range 2.0–3.7) for women
who were referred routinely to gynaecology.
Conclusion Overall, shorter diagnostic delays were seen when a
cancer was suspected, even if the primary tumour site was not
recognised to be ovarian. Despite differences in carcinogenesis and
stage for Type I and Type II iEOC, time to diagnosis and symptoms
were similar. Referral patterns were different, implying subtle
symptom differences. If symptom-based interventions are to impact
on ovarian cancer survival, it is likely to be through reduced volume
rather than stage-shift. Further research on histological subtypes is
needed.
Keywords Delays, early diagnosis, ovarian cancer, symptoms,
Type I and II epithelial ovarian cancer.
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Introduction
Ovarian cancer remains the most lethal gynaecological can-
cer in the UK.1 There is an enduring perception that delays
in presentation and onward referral are the root cause.
Diagnosis relies on symptomatic presentation because pop-
ulation-based screening has yet to show a mortality bene-
fit.2 This has led to major efforts to shorten the time to
diagnosis by raising public awareness of symptoms, encour-
aging women to present earlier, and issuing guidance
encouraging primary-care physicians to investigate women
with a given symptom profile.3–5
Numerous studies6–14 have examined time to ovarian
cancer diagnosis intervals, with median symptom onset to
diagnosis varying from <1 month8 to >12 months.7,12
Common to all the reports is the underlying premise that
ovarian cancer is a single disease entity. This is at odds
with our understanding that ovarian cancer is a heteroge-
neous disease, and that the key to improving outcomes is
focusing on invasive epithelial ovarian cancer (iEOC), par-
ticularly the more aggressive high-grade serous carcino-
mas.15 There is growing consensus that iEOC consists of
five histological subtypes (low-grade serous, clear cell,
endometrioid, mucinous and high-grade serous cancers),
which differ in their underlying biology.
Invasive epithelial ovarian cancer can be grouped broadly
into indolent Type I cancers (comprising low-grade serous,
clear cell, endometrioid, mucinous) that are often diag-
nosed at early stages with more favourable prognosis, and
highly aggressive, rapidly evolving Type II tumours (high-
grade serous and its variants) that are typically diagnosed
at advanced stages and are associated with poor survival.16–
18 Type I tumours are thought to develop in a stepwise
fashion from benign/borderline ovarian neoplasms,19,20
whereas accumulating evidence suggests that Type II can-
cers arise from precursor lesions in the fallopian tubes.18
While type-specific classification is likely to be an oversim-
plification of non high-grade serous histotypes,21,22 it
broadly represents two groups of interest; aggressive, rap-
idly advancing tumours and slow-growing tumours. We
hypothesised that if time to diagnosis rather than biology
was a major contributor to stage at diagnosis, the signifi-
cant stage differences in the two iEOC subtypes should be
accompanied by differences in symptoms and time to diag-
nosis. This is important because many symptom awareness
efforts are underway with little evidence to suggest that a
symptoms-based tool could achieve earlier diagnosis.
This paper aims to provide the first estimates of time-to-
diagnosis intervals for Type I versus Type II iEOC using
two different data sources (patient questionnaires and pri-
mary-care records) in a multicentre setting. We also com-
pare intervals for borderline tumours versus iEOC.
Methods
We obtained the relevant ethics approval from the Joint
University College London/University College Hospital
London Research Ethics Committee (05/Q0505/58). All
participants provided written informed consent and were
enrolled in the UK Ovarian Cancer Population Study
(UKOPS—a biobank case–control study). Recruitment was
from ten centres across England, Wales and Northern
Ireland between February 2006 and February 2008. We
only included women aged ≥45 years with primary EOC
(International Classification of Diseases tenth revision, code
C56) who were recruited before definitive diagnosis or
treatment.
Confirmation of diagnosis
An independent gynaecological oncologist confirmed the
original diagnosis [morphology, grade and International
Federation of Gynecology and Obstetrics (FIGO) stage] by
review of pathology/cytology reports and relevant hospital
records (surgery notes, discharge summaries, multidisci-
plinary team summaries and other correspondence). The
EOC were classified into borderline and invasive EOC. We
grouped the iEOC into Type I (low-grade serous, low/mod-
erate-grade endometrioid, clear cell and mucinous cancers)
and Type II [moderate/high-grade serous, high-grade endo-
metrioid, undifferentiated, malignant mixed mesodermal
(carcinosarcomas)] cancers.22,23 Borderline tumours with
their excellent survival rates, younger age of onset, differing
risk factors and favourable response to surgery were
assessed separately from iEOC. Although borderlines were
included under Type I in the original proposed model,16
the growing consensus has been to exclude them from
analysis of Type I and Type II cancers and restrict the focus
to iEOC.23–25
Symptom ascertainment
Symptom ascertainment has been described previously.26
Briefly, symptom data were collected before diagnosis using
two methods: a self-completed questionnaire (Q) and
review of primary-care records (general practitioner
records; GP). We used a checklist of ovarian cancer symp-
toms (pelvic/abdominal pain or discomfort, increase in
abdominal size, abdominal bloating, abdominal lump, indi-
gestion, diarrhoea, constipation, nausea/vomiting, irregular
vaginal bleeding, urinary frequency or urgency, fatigue, loss
of appetite, weight loss, back pain).
Only symptoms that were new within 15 months
before diagnosis were included in the analysis (to
exclude longstanding symptoms unrelated to the diagno-
sis of cancer). This cut-off was the longest interval, such
that symptoms in cases were more common than in
controls.27
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First symptom
To assess whether first symptom(s) differed by tumour
type, we grouped symptoms into abdominal (pelvic/
abdominal pain or discomfort, increase in abdominal size,
abdominal bloating, abdominal lump), gastrointestinal
(indigestion, diarrhoea, constipation, change in bowel
habit, nausea/vomiting), gynaecological (irregular vaginal
bleeding), urinary (frequency or urgency) or systemic (fati-
gue, weight loss, loss of appetite).
Time intervals
We followed the Aarhus statement28 and used clearly
defined key time-points (see Supplementary material,
Appendix S1). We only used questionnaire data to calculate
patient intervals because symptom-onset dates are rarely
recorded in primary-care records. Similarly, primary-care
records were used to calculate diagnostic intervals because
they contained the most accurate dates for first presenta-
tion.
First referral
We used medical record data (primary-care records, hospi-
tal letters, multidisciplinary team summaries) to identify
the mode and date of first referral. We grouped referrals
into (1) 2-week cancer referral to gynaecological oncology,
(2) 2-week cancer referral to nongynaecological specialties,
(3) routine referral to general gynaecology, (4) routine
referral to nongynaecological specialties, and (5) accident
and emergency (this last group was included because 24%
of cancers in the UK are diagnosed via emergency presenta-
tions).29
Statistical analysis
We hypothesised that if time to diagnosis was a significant
contributor to stage at diagnosis, then time-to-diagnosis
intervals should be different between the biologically dispa-
rate Type I and Type II iEOC. Specifically, we expected
longer time to diagnosis to be associated with more
advanced stage in Type I iEOC, but not in Type II iEOC
(because of aggressive disease/rapid progression). We also
reasoned that women with Type II iEOC would be more
symptomatic and have different referral patterns compared
with Type I iEOC. To examine our hypotheses, we com-
pared time-to-diagnosis intervals and first symptom fre-
quency by tumour type: Type I versus Type II iEOC
subtypes and for borderline tumours versus all invasive
EOC tumours.
We calculated the proportion of women who had patient
and diagnostic intervals of 0 to <3, ≥3 to <6, ≥6 to <9 and
≥9 months for each tumour group. We adjusted patient
intervals to accommodate for missing symptom dates by
multiplying the proportion of women with known symp-
tom dates by the proportion of all women with a
symptom. This seemed reasonable because the proportion
of women with no calculable interval due to missing onset
dates was similar for Type I (77%) and Type II (79%)
iEOC.
To assess if first referral differed according to tumour
type, for each referral mode and tumour type we compared
the proportion of women and the median time from first
referral to diagnosis.
The chi-square test (or Fisher’s exact test when expected
cell frequency was less than five) was used to assess the
relationship between first symptom type and tumour type
(Type I versus II iEOC and borderline versus iEOC). A
stratified Wilcoxon rank sum test30 was used to assess the
relationship between tumour type (Type I versus Type II)
and categorical time intervals, and between total interval
and stage, separately for Type I and Type II tumours. We
assessed the relationship between patient/diagnostic inter-
vals and FIGO stage for Type I and Type II cancers sepa-
rately using the Wilcoxon rank sum test.
All statistical analyses were performed using STATA 12
(StataCorp, College Station, TX, USA). A P-value of <0.05
was considered statistically significant. All statistical tests
were two-sided.
Results
A total of 227 women with newly diagnosed primary EOC
were recruited between 2006 and 2008. Of these women,
194 had invasive EOC and 33 had borderline epithelial
ovarian tumours. In all, 222 (98%) completed question-
naires, primary-care records were received for 199 (88%)
women and for 194 (85%) women we had both. Of the
iEOC, 60 were Type I (six low-grade serous, 13 low-grade
endometrioid, 17 clear cell, 19 mucinous, five low grade
mixed) and 134 were Type II (98 high-grade serous, nine
high-grade endometrioid, three undifferentiated, ten carci-
nosarcoma, one transitional, eight adenocarcinoma, five
high-grade mixed) iEOC.
Table 1 details demographic and clinical details for
women with Type I and Type II iEOC and borderline
tumours. Women across all tumour groups were similar
for age at diagnosis (mean age between 62 and 65 years)
and ethnicity (≥ 95% White). Approximately 90% of
women with Type II iEOC and borderline tumours were
postmenopausal, but only 75% of women with Type I
iEOC were postmenopausal. As expected, a higher propor-
tion (78%) of Type I than Type II (21%) had early stage
(I/II) disease. Among those with borderline tumours, 73%
had early-stage disease.
First symptom
The first symptom reported was similar for Type I and II
cancers with the exception of more irregular vaginal bleed-
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ing (almost all postmenopausal) in Type I (Q: 15% versus
4%, P = 0.01) (see Table 2). Abdominal symptoms were
the most common (Q: Type I 77% and Type II 65%),
whereas gynaecological symptoms were the least common
(Q: Type I 15% and Type II 4%). The reporting of bloating
and increased abdominal size was three to four times
higher on questionnaire than in primary-care records (e.g.
Type II bloating 40% Q versus 9% GP).
Borderline tumours had more urinary frequency/urgency
than iEOC (25% versus 10%, P = 0.04) recorded as their
first symptom in primary-care records and none had sys-
temic symptoms.
Time to diagnosis intervals
Patient and diagnostic intervals were similar for Type I and
Type II iEOC, although a higher proportion of women
with Type I presented within 3 months of symptom onset
(Table 3). Total intervals were also comparable: 6.5 months
(interquartile range 2.8–10.4) for Type I versus 7.2 months
(interquartile range 3.9–12.8) for Type II.
For both Type I and Type II, median patient intervals
were short (within 1 month) and median diagnostic inter-
vals were several months longer than patient intervals (see
Supplementary material, Table S1).
In all, 12.2% of women with Type I and 8.1% with Type
II cancers delayed presentation for ≥ 9 months (Table 3),
and 27% of women with Type I and Type II iEOC had
diagnostic intervals of ≥ 9 months.
There were no significant trends between time-to-diag-
nosis intervals and cancer stage in either Type I or Type II
tumours (Table 3 and see Supplementary material, Fig-
ure S1a,b). Furthermore, 19% (3/16) of women with Type
II had early-stage disease despite long total intervals of at
least 9 months and 43% (3/7) of Type I had late-stage dis-
ease despite having short total intervals (see Supplementary
material, Table S2). However, all intervals were more likely
to be longer in late-stage than in early-stage disease.
Mode of referral
Fourteen women were diagnosed as a result of incidental
findings (six Type I, seven Type II, one borderline) and
referral pathways were unknown for 11 women. In the
remaining women, the most common initial referral across
all tumour types was a 2-week cancer referral to gynaeco-
logical oncology (ranging from 34% for Type II to 60% for
borderline tumours). A higher proportion of women with
Type I versus Type II cancers had a 2-week cancer referral
to gynaecological oncology (P = 0.005), whereas more Type
II women had a routine referral to nongynaecological spe-
cialties (P = 0.17) (Table 4). Higher proportion of border-
line compared with iEOC had a 2-week cancer referral to
gynaecological oncology (P = 0.05); however, numbers
were small.
Time from first referral to diagnosis according to referral
mode was comparable for Type I versus Type II tumours.
Excluding the women who presented as emergencies, time
from referral to diagnosis was typically 1 month longer for
routine referrals both to general gynaecology and nongy-
naecological departments. Following referral, women with
borderline tumours took longer than women with iEOC to
be diagnosed.
Discussion
Main findings
To our knowledge, this is the first study to examine time-
to-diagnosis intervals in iEOC grouped into the molecularly
and clinically distinct Type I and Type II iEOC. Despite
expected large differences in stage distribution, we found
no differences in time-to-diagnosis intervals in women with
Type I compared with Type II iEOC. Symptom profiles
were also broadly comparable for all cancer groups, imply-
ing that symptoms may not reflect underlying tumour
biology and pathogenesis. An exception to this was that
more Type I than Type II cancers had initial symptoms of
Table 1. Demographics and clinical details (n = 227)
Type I iEOC
(n = 60)
Type II iEOC
(n = 134)
Borderline
ovarian tumours
(n = 33)
Age at diagnosis, (years)
Mean (SD) 62.2 (10.7) 65.3 (9.8) 63.9 (12.2)
Range 46–83 46–90 45–87
Ethnicity
White 57 (95%) 130 (97%) 33 (100%)
Other 3 (5%) 4 (3%) 0 (0%)
Menopausal status
Unknown 5 (8%) 1 (1%) –
Perimenopausal 10 (17%) 14 (10%) 3 (9%)
Postmenopausal 45 (75%) 119 (89%) 30 (91%)
Using HRT 9 (20%) 43 (36%) 8 (27%)
Not using HRT 28 (62%) 65 (55%) 21 (70%)
Unknown if
using HRT
8 (18%) 11 (9%) 1 (3%)
FIGO stage
I 42 (70%) 14 (10%) 24 (73%)
II 5 (8%) 14 (10%) 0 (0%)
III 11 (18%) 80 (60%) 3 (9%)
IV 2 (3%) 25 (19%) 0 (0%)
Unstaged – 1 (1%) 6 (18%)
Tumour grade
1 23 (38%) – NA
2 18 (30%) 22 (16%)
3 12 (20%) 91 (68%)
Unknown 7 (12%) 21 (16%)
HRT, hormone replacement therapy.
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irregular vaginal bleeding (a red flag symptom for gynaeco-
logical malignancy). However, this was an infrequent symp-
tom. Despite apparently similar symptom profiles, the
referral patterns were different among tumour groups. The
fact that more women with Type I than Type II iEOC were
first referred for a suspected gynaecological malignancy sug-
gests that there are subtle differences in symptom severity,
frequency or progression that we were unable to disentangle.
Strengths and limitations
A major strength of this study is that we used two differ-
ent sources to collect data on time intervals to ovarian
cancer diagnosis – onset of symptoms directly from
patients, date of first presentation from primary-care
records and date of diagnosis from secondary care histol-
ogy records. Using this approach, the high sensitivity of
each source for a particular data item was maximised. To
truly combine the data into a single interval from symp-
tom onset to diagnosis requires a complex algorithm which
we are currently developing. Other strengths include the
multicentre design involving ten gynaecological oncology
centres across the UK, thereby providing a more represen-
tative sample.
It is possible that subtle differences between clear cell and
endometrioid tumours have been masked by our Type I/II
grouping.31 Nevertheless, we feel that within the context of
the aims of our study (to estimate time to diagnosis accord-
ing to a broad dichotomy of aggressive, rapidly advancing
cancers versus indolent cancers with favourable prognoses)
our chosen grouping would have minimal impact on the
outcomes of interest. A gynaecological oncologist reviewed
all pathology and related records and confirmed diagnosis.
Central pathological review was not undertaken before this
analysis. Although there is evidence of discordance in histo-
Table 2. Nature of first symptom by tumour group
Questionnaire GP notes Questionnaire GP notes
Type I iEOC
(n = 57)
Type II iEOC
(n = 132)
Type I iEOC
(n = 54)
Type II iEOC
(n = 117)
iEOC
(n = 189)
Borderline
(n = 33)
iEOC
(n = 171)
Borderline
(n = 28)
Women with symptom n = 53 n = 124 n = 48 n = 110 (n = 177) (n = 26) (n = 158) (n = 24)
Abdominal
≥1 abdominal
first symptom
41 (77%) 80 (65%) 23 (48%) 51 (46%) 121 (68%) 20 (77%) 74 (47%) 10 (42%)
Pelvic/abdominal
pain/discomfort
21 (40%) 40 (32%) 14 (29%) 31 (28%) 61 (34%) 8 (31%) 45 (28%) 6 (25%)
Increase in abdominal size 23 (43%) 43 (35%) 8 (17%) 11 (10%) 66 (37%) 11 (42%) 19 (12%) 3 (13%)
Abdomen feels bloated 22 (42%) 49 (40%) 5 (10%) 10 (9%) 71 (40%) 13 (50%) 15 (9%) 0 (0%)
Able to feel a lump in
abdomen
5 (9%) 9 (7%) 2 (4%) 6 (5%) 14 (8%) 4 (15%) 8 (5%) 3 (13%)
Gastrointestinal (GI)
≥1 GI first symptom 16 (30%) 42 (34%) 14 (29%) 36 (33%) 58 (33%) 5 (19%) 50 (32%) 5 (21%)
Indigestion 5 (9%) 21 (17%) 4 (8%) 11 (10%) 26 (15%) 3 (12%) 15 (9%) 1 (4%)
Constipation 7 (13%) 19 (15%) 4 (8%) 8 (7%) 26 (15%) 2 (8%) 12 (8%) 2 (8%)
Diarrhoea 2 (4%) 11 (9%) 1 (2%) 4 (4%) 13 (7%) 2 (8%) 5 (3%) 1 (4%)
Change in bowel habit 1 (2%) 1 (1%) 1 (2%) 10 (9%) 2 (1%) 0 (0%) 11 (7%) 2 (8%)
Nausea or vomiting 8 (15%) 8 (6%) 5 (10%) 7 (6%) 16 (9%) 2 (8%) 12 (8%) 0 (0%)
Gynaecological
Irregular vaginal bleeding 8 (15%) 5 (4%)* 6 (13%) 4 (4%)* 13 (7%) 1 (4%) 10 (6%) 2 (8%)
Urinary
Urinary frequency or urgency 9 (17%) 17 (14%) 8 (17%) 8 (15%) 26 (15%) 8 (31%) 16 (10%) 6 (25%)*
Systemic
≥1 systemic first symptom 20 (38%) 54 (44%) 5 (10%) 17 (15%) 74 (42%) 6 (23%) 22 (14%) 0 (0%)*
Loss of appetite 6 (11%) 20 (16%) 0 (0%) 5 (5%) 26 (15%) 2 (8%) 5 (3%) 0 (0%)*
Weight loss 10 (19%) 17 (14%) 1 (2%) 7 (6%) 27 (15%) 1 (4%) 8 (5%) 0 (0%)*
Fatigue 11 (21%) 34 (27%) 4 (4%) 10 (9%) 45 (25%) 4 (15%) 14 (9%) 0 (0%)*
Other
Back pain 4 (8%) 13 (10%) 3 (6%) 13 (12%) 17 (10%) 2 (8%) 16 (10%) 2 (8%)
Women may have more than one-first symptom type. Percentages are calculated with the number of women who reported a (new checklist)
symptom on each source as the denominator.
*P < 0.05.
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logical subtyping between local and expert review, this relates
to reclassification of high-grade endometrioid, high-grade
mixed and undifferentiated into high-grade serous.32 This
was anticipated when we undertook our classification into
Type I and Type II disease and therefore does not affect our
analysis. Although women were systematically approached,
selection bias was inevitable in common with all studies
based on individual consent. Another limitation was that
patient interval data were based on retrospective report,
which can give rise to recall bias and recall error. Although
for any systematic errors in symptom reporting (i.e. recall
bias), the bias would have been the same for our main com-
parator groups because women did not know if they had
Type I or Type II iEOC at the time of questionnaire comple-
tion. In addition, women may not have recalled symptom
details accurately because of memory decay (recall error).
This could have resulted in overestimation or underestima-
tion of patient intervals. We minimised this by collecting
questionnaire data at or before definitive diagnosis. Small
numbers in subgroups limited some of our assessments.
Finally, six of the women in the current analysis were
enrolled in the control (no intervention) arm of the UK Col-
laborative Trial of Ovarian Cancer Screening (UKCTOCS). It
is possible that these women were more health aware but
given that the healthy volunteer effect decreases with time
from randomisation,33 it is of note that recruitment to UKC-
TOCS was completed in 2005 and the above six women were
diagnosed between 2006 and 2008.
Interpretation
Our patient and diagnostic intervals are comparable to
those previously reported (medians between 1 and
4 months).10,12,14,34 Also in corroboration of our findings,
a large population-based case–control study in Australia
reported no difference in time-to-diagnosis intervals for
early- versus late-stage iEOC.6 We are only aware of one
other study35 that examined time to diagnosis of EOC by
histological subtype. They found that women with serous
ovarian cancer had longer mean patient intervals compared
with other histological types of epithelial ovarian cancer
(12 weeks versus 7 weeks, P < 0.05).
The short median patient intervals in our study belie the
fact that one in five women with iEOC reported having
symptoms for at least 6 months before presenting.
Recently, an International Cancer Benchmarking Partner-
ship study identified increased perceived barriers to symp-
tomatic presentation in the UK compared with similar
European countries, especially concern about wasting the
doctor’s time.36 Despite the recruitment period being
2006–08, there were considerable delays in diagnosis with
one in four women with iEOC (whether Type I or II)
experiencing diagnostic intervals of ≥ 9 months. Most
women were not referred appropriately, only 41% with
iEOC were initially referred to gynaecological oncology.
Nevertheless, time from referral to diagnosis was similar
for all 2-week cancer referrals, indicating that suspecting
malignancy is more important than diagnosing the correct
cancer site. This most likely reflects the reorganisation of
cancer services in the National Health Service in the UK,
which ensures multidisciplinary review of all new cases in a
timely manner with strict standards on time to treatment
from primary-care referral.
If time to diagnosis was a significant contributor to stage
at diagnosis, then patient and diagnostic intervals should
be different between the biologically disparate Type I and
Type II iEOC. Instead it seems that the link between symp-
toms and tumour biology in ovarian cancer is complex and
that a symptom-based intervention may not result in ear-
lier stage diagnosis of Type II iEOC.
The fact that upper quartiles for late stage intervals tended
to be longer than for early stage indicated a bimodal distribu-
tion for late stage: either short because of very aggressive dis-
ease or long leading to advanced disease. Our findings are in
Table 3. Patient and diagnostic intervals (months) for Type I and II
tumours and according to early versus late stage
Type I iEOC Type II iEOC
Patient interval (n = 57) (n = 132)
No. with symptom 53 124
No. with interval 41 98
0 to < 3 m* 29 (70.1%) 64 (51.6%)
3 to < 6 m* 2 (4.8%) 17 (13.7%)
6 to < 9 m* 5 (12.2%) 7 (5.6%)
≥ 9 m* 5 (12.2%) 10 (8.1%)
Median months (IQR)
Early stage 0.3 (0.3–3.0) n = 33 1.0 (0.3–4.0) n = 18
Late stage 0.3 (0.3–4.5) n = 8 1.8 (0.3–5.0) n = 79
Diagnostic
interval
(n = 54) (n = 117)
No. with
symptom
48 110
No. with
interval
48 110
0 to <3 m 23 (47.9%) 44 (40.0%)
3 to <6 m 10 (20.8%) 29 (26.4%)
6 to < 9 m 2 (4.2%) 7 (6.4%)
≥9 m 13 (27.1%) 30 (27.3%)
Median months (IQR)
Early stage 3.0 (2.0–6.1) n = 37 3.5 (2.2–6.4) n = 24
Late stage 3.7 (1.3–12.8) n = 11 4.1 (1.7–9.8) n = 86
IQR, interquartile range.
*Adjusted by multiplying number of women in interval by proportion
of women with symptoms who had an estimable interval.
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keeping with emerging data on the natural history of high-
grade serous iEOC where modelling suggests that early in the
course of disease at a median diameter of about 3 cm, serous
ovarian cancers progress to an advanced stage (stage III or
IV).37 This suggests that in Type II iEOC a symptom-based
intervention is more likely to influence tumour volume than
impact on stage. This is supported by the recent prospective
study (DOvE study; Diagnosing Ovarian Cancer Early)38
where CA125 testing and transvaginal ultrasound in women
with ovarian cancer symptoms resulted in detection of lower
volume disease in women with high-grade serous ovarian
cancers.39 Diagnosis at lower tumour volumes is likely to
improve the surgeon’s ability to achieve zero residual disease
at surgery, a key prognostic factor in disease survival.40 In
addition, less intra-tumour heterogeneity may lead to a bet-
ter response to chemotherapy.
The drive by service providers and patients to raise
symptom awareness and introduce systematic CA125 and
ultrasound testing in primary care is understandable given
the continued significant delays in diagnosis. In our study,
one in four women had diagnostic intervals >9 months.
However, given the prevalence and non-specific nature of
symptoms41 the significant resource implications and
potential harm to symptomatic women without ovarian
cancer,42 it remains controversial as to whether or not cur-
rent evidence is adequate to support practice change or a
prospective randomised controlled trial of a symptom-
based intervention is needed to comprehensively assess
impact.
Conclusion
Overall, shorter diagnostic delays were seen when a cancer
was suspected, even if the primary tumour site was not
recognised to be ovarian. Despite differences in tumour
biology, carcinogenesis and stage at diagnosis, no difference
in time to diagnosis for Type I and II ovarian cancers was
noted. However, the pattern of referral was different,
implying that there may be subtle differences in symptoms.
If symptom-based interventions impact on survival, it is
unlikely to be through stage shift. Further research focused
on histological subtypes is needed.
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